About Biohaven
Biohaven is a company based in New Haven (United States) founded in 2022 was acquired by Pfizer in October 2022. The company has 256 employees as of December 31, 2024. Biohaven offers products and services including Nurtec ODT and Zavzpret. Biohaven operates in a competitive market with competitors including Jazz Pharmaceuticals, Lundbeck, Kriya Therapeutics, Sana Biotechnology and PureTech Health, among others.
- Headquarter New Haven, United States
- Employees 256 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Biohaven Ltd.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Biohaven
Biohaven is a publicly listed company on the NYSE with ticker symbol BHVN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Biohaven
Biohaven offers a comprehensive portfolio of products and services, including Nurtec ODT and Zavzpret.
Oral therapy for acute and preventive migraine relief.
Nasal spray for treating migraine attacks effectively.
People of Biohaven
Unlock access to complete
Unlock access to complete
Funding Insights of Biohaven
Investors in Biohaven
Biohaven has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Pfizer and Oberland Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Structured financing solutions are provided for the global healthcare industry by Oberland Capital.
|
Locked | Locked | Locked | |
|
Pharmaceutical products for treating multiple diseases are provided.
|
Locked | Locked | Locked |
Investor details for Biohaven
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Biohaven
Investment portfolio details for Biohaven
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Biohaven
Detailed financials for Biohaven
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Biohaven Comparisons
Peer comparison for Biohaven
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Biohaven
Biohaven operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Lundbeck, Kriya Therapeutics, Sana Biotechnology and PureTech Health, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Drugs for CNS disorders are developed and advanced.
|
|
| Locked | Locked | Locked |
Developer of therapeutic solutions for the treatment of diabetes
|
|
| Locked | Locked | Locked |
Genetically engineered cell therapies are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
|
|
| Locked | Locked | Locked |
Therapies for neurological and neuropsychiatric diseases are developed.
|
Detailed competitors of Biohaven
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Biohaven
Complete news archive for Biohaven
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Biohaven
Biohaven was founded in 2022 and raised its 1st funding round 3 years after it was founded.
Biohaven is headquartered in New Haven, United States. It is registered at New Haven, Connecticut, United States.
As of Dec 31, 2024, the latest employee count at Biohaven is 256.
Biohaven was founded in 2022 and is headquartered in New Haven, United States. Focus is placed on the development of therapeutics targeting neurological and neuropsychiatric conditions within the biotechnology sector. Proprietary platforms are utilized, including Kv7 ion channel modulation for epilepsy and neuronal hyperexcitability, glutamate modulation for obsessive-compulsive disorder, spinocerebellar ataxia, and myostatin inhibition for neuromuscular diseases. Operations emphasize drug discovery and clinical advancement in these areas.
Biohaven's top competitors include Jazz Pharmaceuticals, Biohaven Pharmaceutical and Sana Biotechnology.
Biohaven offers Nurtec ODT and Zavzpret.
Yes, Biohaven is publicly traded on NYSE under the ticker symbol BHVN.
Biohaven has 2 investors. Key investors include Pfizer, and Oberland Capital.
The ticker symbol of Biohaven is BHVN on NYSE.